2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
2
Interventional
2
Sponsor
Conditions
Breast Neoplasms
10184
Neoplasms
7810
Carcinoma, Non-Small-Cell Lung
5760
Prostatic Neoplasms
5024
Colorectal Neoplasms
4606
Lung Neoplasms
3725
Leukemia, Myeloid, Acute
3102
Neoplasm Metastasis
3083
Multiple Myeloma
3082
Pancreatic Neoplasms
2845
Melanoma
2653
Ovarian Neoplasms
2573
Lymphoma
2571
Carcinoma, Hepatocellular
2480
Stomach Neoplasms
2330
Recurrence
2230
Head and Neck Neoplasms
2103
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2086
Lymphoma, Non-Hodgkin
2058
Leukemia
2013
Brain Neoplasms
1905
Glioblastoma
1797
Colonic Neoplasms
1791
Leukemia, Lymphocytic, Chronic, B-Cell
1771
Rectal Neoplasms
1720
Uterine Cervical Neoplasms
1693
Squamous Cell Carcinoma of Head and Neck
1654
Lymphoma, Follicular
1652
Lymphoma, Large B-Cell, Diffuse
1597
Carcinoma, Renal Cell
1577
Interventions
VP-102
1
Cantharidin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Skin Diseases, Viral
×
Clear all
NCT03487549
2024-11-27
COVE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
56 enrolled
29 charts
NCT03981822
2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
105 enrolled
24 charts